Altered Prion Protein Expression Pattern in CSF as a Biomarker for Creutzfeldt-Jakob Disease

Creutzfeldt-Jakob disease (CJD) is the most frequent human Prion-related disorder (PrD). The detection of 14-3-3 protein in the cerebrospinal fluid (CSF) is used as a molecular diagnostic criterion for patients clinically compatible with CJD. However, there is a pressing need for the identification of new reliable disease biomarkers. The pathological mechanisms leading to accumulation of 14-3-3 protein in CSF are not fully understood, however neuronal loss followed by cell lysis is assumed to cause the increase in 14-3-3 levels, which also occurs in conditions such as brain ischemia. Here we investigated the relation between the levels of 14-3-3 protein, Lactate dehydrogenase (LDH) activity and expression of the prion protein (PrP) in CSF of sporadic and familial CJD cases. Unexpectedly, we found normal levels of LDH activity in CJD cases with moderate levels of 14-3-3 protein. Increased LDH activity was only observed in a percentage of the CSF samples that also exhibited high 14-3-3 levels. Analysis of the PrP expression pattern in CSF revealed a reduction in PrP levels in all CJD cases, as well as marked changes in its glycosylation pattern. PrP present in CSF of CJD cases was sensitive to proteases. The alterations in PrP expression observed in CJD cases were not detected in other pathologies affecting the nervous system, including cases of dementia and tropical spastic paraparesis/HTLV-1 associated myelopathy (HAM/TSP). Time course analysis in several CJD patients revealed that 14-3-3 levels in CSF are dynamic and show a high degree of variability during the end stage of the disease. Post-mortem analysis of brain tissue also indicated that 14-3-3 protein is upregulated in neuronal cells, suggesting that its expression is modulated during the course of the disease. These results suggest that a combined analysis of 14-3-3 and PrP expression pattern in CSF is a reliable biomarker to confirm the clinical diagnosis of CJD patients and follow disease progression.

[1]  C. Soto.  Prion hypothesis: the end of the controversy? , 2011, Trends in biochemical sciences.

[2]  J. Collinge,et al.  Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay , 2011, The Lancet.

[3]  Steven J Collins,et al.  Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion , 2011, Nature Medicine.

[4]  C. Hetz,et al.  Prion Protein Misfolding Affects Calcium Homeostasis and Sensitizes Cells to Endoplasmic Reticulum Stress , 2010, PloS one.

[5]  Mick F. Tuite,et al.  The prion hypothesis: from biological anomaly to basic regulatory mechanism , 2010, Nature Reviews Molecular Cell Biology.

[6]  Per Westermark,et al.  Prion-like aggregates: infectious agents in human disease. , 2010, Trends in molecular medicine.

[7]  Beat Meier,et al.  Prions , 2010 .

[8]  U. Heinemann,et al.  Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. , 2009, Journal of Alzheimer's disease : JAD.

[9]  J. Collinge,et al.  Detection and characterization of proteinase K-sensitive disease-related prion protein with thermolysin , 2008, The Biochemical journal.

[10]  J. Castilla,et al.  Perturbation of Endoplasmic Reticulum Homeostasis Facilitates Prion Replication* , 2007, Journal of Biological Chemistry.

[11]  J. Oger,et al.  Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). , 2006, AIDS research and human retroviruses.

[12]  C. Hetz,et al.  Stressing out the ER: a role of the unfolded protein response in prion-related disorders. , 2006, Current molecular medicine.

[13]  D. Wildman,et al.  Proapoptotic BAX and BAK Modulate the Unfolded Protein Response by a Direct Interaction with IRE1a , 2006 .

[14]  N. Hooper,et al.  Reactive Oxygen Species-mediated β-Cleavage of the Prion Protein in the Cellular Response to Oxidative Stress* , 2005, Journal of Biological Chemistry.

[15]  N. Hooper,et al.  Reactive oxygen species (ROS)-mediated β-cleavage of the prion protein in the mechanism of the cellular response to oxidative stress , 2005 .

[16]  J. Castilla,et al.  The Disulfide Isomerase Grp58 Is a Protective Factor against Prion Neurotoxicity , 2005, The Journal of Neuroscience.

[17]  S. Prusiner,et al.  Diagnosis of human prion disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Hetz,et al.  Prion replication alters the distribution of synaptophysin and caveolin 1 in neuronal lipid rafts. , 2004, The American journal of pathology.

[19]  R. Castellani,et al.  Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease , 2004, Neurology.

[20]  J. Castilla,et al.  Caspase‐12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein , 2003, The EMBO journal.

[21]  D. Berg,et al.  14-3-3 proteins in the nervous system , 2003, Nature Reviews Neuroscience.

[22]  S. Marie,et al.  14-3-3 protein in the CSF of patients with rapidly progressive dementia , 2003, Neurology.

[23]  N. Barbaro,et al.  Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. , 2003, Archives of neurology.

[24]  M. Schachner,et al.  Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival , 2003, Molecular and Cellular Neuroscience.

[25]  Claudio Soto,et al.  Unfolding the role of protein misfolding in neurodegenerative diseases , 2003, Nature Reviews Neuroscience.

[26]  H. Baxter,et al.  Immunolocalisation of 14-3-3 isoforms in normal and scrapie-infected murine brain , 2002, Neuroscience.

[27]  I. Zerr,et al.  Clinical diagnosis and differential diagnosis of CJD and vCJD , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[28]  J. Laplanche,et al.  CSF detection of the 14-3-3 protein in unselected patients with dementia. , 2002, Neurology.

[29]  A. Green,et al.  Absence of protease‐resistant prion protein in the cerebrospinal fluid of Creutzfeldt–Jakob disease , 2001, The Journal of pathology.

[30]  D. McKeel,et al.  Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt–Jakob disease , 2000, Neurology.

[31]  J. Laplanche,et al.  Signal transduction through prion protein. , 2000, Science.

[32]  M. Eigen,et al.  Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Haltia,et al.  Human prion diseases , 2000, Annals of medicine.

[34]  J. Kornhuber,et al.  Isoform Pattern of 14‐3‐3 Proteins in the Cerebrospinal Fluid of Patients with Creutzfeldt‐Jakob Disease , 1999, Journal of neurochemistry.

[35]  B. Steinhoff,et al.  How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. , 1999, Brain : a journal of neurology.

[36]  J. Laplanche,et al.  14-3-3 Protein, Neuron-Specific Enolase, and S-100 Protein in Cerebrospinal Fluid of Patients with Creutzfeldt-Jakob Disease , 1998, Dementia and Geriatric Cognitive Disorders.

[37]  Stanley B. Prusiner,et al.  Nobel Lecture: Prions , 1998 .

[38]  O. Gefeller,et al.  Detection of 14‐3‐3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt‐Jakob disease , 1998, Annals of neurology.

[39]  C. Gibbs,et al.  The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. , 1996, The New England journal of medicine.

[40]  S. DeArmond,et al.  Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. , 1996, Archives of neurology.

[41]  K. Jellinger,et al.  Neuropathological Diagnostic Criteria for Creutzfeldt‐Jakob Disease (CJD) and Other Human Spongiform Encephalopathies (Prion Diseases) , 1995, Brain pathology.

[42]  A Aitken,et al.  Expression and structural analysis of 14-3-3 proteins. , 1995, Journal of molecular biology.

[43]  J. Rostas,et al.  Subcellular Localisation of 14‐3‐3 Isoforms in Rat Brain Using Specific Antibodies , 1994, Journal of Neurochemistry.

[44]  W. Fantl,et al.  Activation of Raf-1 by 14-3-3 proteins , 1994, Nature.

[45]  P. Brown,et al.  Familial Creutzfeldt-Jakob disease in Chile is associated with the codon 200 mutation of the PRNP amyloid precursor gene on chromosome 20 , 1992, Journal of the Neurological Sciences.

[46]  F. Tagliavini,et al.  A soluble form of prion protein in human cerebrospinal fluid: implications for prion-related encephalopathies. , 1992, Biochemical and biophysical research communications.

[47]  L. Cartier,et al.  [Clinical analysis of a series of 69 definitive cases of Jakob-Creutzfeldt disease occurring in Chile between 1960 and 1985]. , 1987, Revista medica de Chile.

[48]  Stanley B. Prusiner,et al.  Scrapie prion protein contains a phosphatidylinositol glycolipid , 1987, Cell.